Important Information for Regeneron Pharmaceuticals Investors: Class Action Lawsuit Filed
On February 10, 2025, Robbins Geller Rudman & Dowd LLP announced that investors and acquirers of Regeneron Pharmaceuticals, Inc. (Regeneron) securities between November 2, 2023, and October 30, 2024, both dates inclusive (the “Class Period”), have until March 10, 2025, to seek appointment as lead plaintiff in a securities class action lawsuit. The lawsuit, Radtke v. Regeneron Pharmaceuticals, Inc., No. 25-cv-00145 (S.D.N.Y.), alleges that Regeneron and certain of its top current and former executives violated the Securities Exchange Act of 1934.
Allegations in the Regeneron Class Action Lawsuit
The complaint alleges that Regeneron and its executives made false and misleading statements regarding the company’s business, financial condition, and prospects. Specifically, the lawsuit alleges that Regeneron failed to disclose that:
- The company’s EYLEA® drug was facing increased competition from biosimilars;
- The company’s Dupixent® drug was experiencing slower-than-expected sales growth;
- Regeneron was experiencing manufacturing issues with its EYLEA® drug;
- The company’s regulatory approvals for certain products were delayed;
As a result of these alleged false and misleading statements, Regeneron’s stock traded at artificially inflated prices during the Class Period.
Impact on Individual Investors
If you purchased or acquired Regeneron securities during the Class Period and suffered losses, you may be able to recover your damages. The lead plaintiff will act on behalf of all class members in the lawsuit. Class members do not need to seek individual representation. To be eligible for appointment as lead plaintiff, you must meet certain legal requirements and be able to demonstrate significant damages.
Impact on the World
The Regeneron class action lawsuit is significant because it highlights the importance of transparency and honesty in the pharmaceutical industry. The alleged misrepresentations could have far-reaching consequences, including:
- Investor confidence in the pharmaceutical industry may be negatively affected;
- Regeneron’s reputation may be damaged, potentially impacting its ability to attract and retain customers and partners;
- Regeneron’s stock price may continue to decline as investors reassess the company’s financial situation;
It is essential that companies provide accurate and truthful information to investors to maintain trust and confidence in the market. Misrepresentations can lead to significant financial losses for individual investors and undermine the integrity of the securities market as a whole.
Conclusion
The Regeneron class action lawsuit is a reminder of the importance of transparency and honesty in the securities market. If you purchased or acquired Regeneron securities during the Class Period and suffered losses, you may be able to recover your damages. Contact Robbins Geller Rudman & Dowd LLP for more information about your rights and potential recovery.
As a responsible investor, it is crucial to stay informed about the companies in which you invest and to be wary of potential misrepresentations. The pharmaceutical industry, in particular, can be subject to significant regulatory scrutiny and competitive pressures, making it essential for companies to provide accurate and transparent information to investors.
Regeneron’s alleged misrepresentations could have far-reaching consequences, including damage to the company’s reputation, investor confidence, and potential regulatory action. It is essential that companies prioritize transparency and honesty to maintain trust and confidence in the market and protect the interests of their investors.
